M201-A
Drug for heart failure, atrial fibrillation and kidney disease
Aetas’ mission is to ‘deliver drugs that delight patients into clinical practice as quickly as possible’. This is our mission and Aetas’ ambition.
News Release
-
2023/11
Phase II clinical trials of M201-A injection for patients with heart failure and renal dysfunction were initiated in the first semester.
-
2021/01
A Phase I repeated-dose study of M201-A injection was completed. We confirmed the effects of M201-A on Na diuresis and improvement of renal function in humans with mild renal dysfunction.
-
2020/03
A dose-escalation, placebo-controlled, double-blind, randomised Phase I repeated-dose study of M201-A hydrochloride injection in healthy adults was initiated.
Development Products
-
Company Philosophy
- ・We are challenging ourselves to explore and develop medicines using creative ideas.
- ・We are focusing on the development of drugs for the treatment of heart and kidney diseases.
-
Business Strategy
- ・We will collaborate with highly specialised researchers to conduct the study and development of unique drugs.
- ・Our aim is to develop first-in-class drugs by confirming their pharmacological effects in animal models.
- ・We will licence our products to pharmaceutical companies both domestically and internationally.
-
Company Profile
We are an academia-initiated bio-venture aiming to develop drugs for unmet medical needs.We are researching and developing novel therapeutic agents for heart and kidney diseases, both of which are increasing in terms of the number of patients in an ageing society.The Company is developing ryanodine receptor 2 inhibitors, K201 and M201-A.